Nabriva Therapeutics (NASDAQ:NBRV) Shares Down 5.4%
Nabriva Therapeutics PLC – (NASDAQ:NBRV)’s share price was down 5.4% during mid-day trading on Wednesday . The company traded as low as $1.73 and last traded at $1.75, approximately 998,200 shares traded hands during mid-day trading. A decline of 13% from the average daily volume of 1,148,051 shares. The stock had previously closed at $1.85.
A number of equities research analysts recently issued reports on NBRV shares. Zacks Investment Research cut Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 23rd. Wedbush restated an “outperform” rating and issued a $5.00 price objective on shares of Nabriva Therapeutics in a research note on Friday, August 9th. Northland Securities set a $13.00 price objective on Nabriva Therapeutics and gave the company a “buy” rating in a research note on Friday, August 16th. HC Wainwright set a $7.00 price objective on Nabriva Therapeutics and gave the company a “buy” rating in a research note on Sunday, August 18th. Finally, Bank of America set a $6.00 target price on Nabriva Therapeutics and gave the company a “buy” rating in a report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $7.06.
The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.56. The firm has a market cap of $1.39 billion, a PE ratio of -1.07 and a beta of 2.43. The stock has a fifty day simple moving average of $2.09 and a two-hundred day simple moving average of $2.35.
In related news, CEO Theodore R. Schroeder bought 50,000 shares of Nabriva Therapeutics stock in a transaction on Tuesday, August 27th. The stock was acquired at an average price of $1.79 per share, with a total value of $89,500.00. Following the acquisition, the chief executive officer now directly owns 5,786 shares of the company’s stock, valued at $10,356.94. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders have acquired 64,977 shares of company stock valued at $119,951 and have sold 21,773 shares valued at $45,186. 3.32% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Commonwealth Equity Services LLC grew its holdings in shares of Nabriva Therapeutics by 30.0% during the second quarter. Commonwealth Equity Services LLC now owns 65,010 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 15,000 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Nabriva Therapeutics by 51.8% during the second quarter. Renaissance Technologies LLC now owns 1,299,365 shares of the biotechnology company’s stock worth $3,157,000 after purchasing an additional 443,600 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Nabriva Therapeutics by 92.7% during the second quarter. JPMorgan Chase & Co. now owns 323,857 shares of the biotechnology company’s stock worth $719,000 after purchasing an additional 155,815 shares in the last quarter. A.R.T. Advisors LLC purchased a new position in shares of Nabriva Therapeutics during the second quarter worth about $90,000. Finally, FMR LLC grew its holdings in shares of Nabriva Therapeutics by 77.0% during the first quarter. FMR LLC now owns 3,261,500 shares of the biotechnology company’s stock worth $7,958,000 after purchasing an additional 1,418,800 shares in the last quarter. 3.89% of the stock is owned by institutional investors.
About Nabriva Therapeutics (NASDAQ:NBRV)
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Featured Article: Why is the ex-dividend date different from the record date?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.